人卵巢癌细胞A2780 (STR)FH0140
价格：￥2000
品牌名称：富衡型号：FH0140 原产地：中国大陆 更新时间：2026/10/21 7:56:21
产品摘要：A2780 细胞系由 J. Fogh 和 J. Trempe 于 1977 年建立。该细胞在体外培养时呈上皮样形态，贴壁生长。它具有一些典型的卵巢癌细胞特征，如高增殖能力、特定的细胞表面抗原表达等。A2780 细胞常被用于卵巢癌的基础研究，包括肿瘤细胞的生物学行为、信号转导通路、药物敏感性等方面的研究。此外，它还可用于筛选和评估新型抗卵巢癌药物的疗效，为卵巢癌的临床治疗提供实验依据。
支付方式：
- 支付宝 微信 银行转账
产品完善度： 访问次数：635
企业档案
会员类型：旗舰版
已获得阿仪网信誉 等级评定
61成长值
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网旗舰版会员：3年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
参观次数：630501
详细内容
| 产品名称 | 人卵巢癌细胞；A2780 (STR) |
|---|---|
| 品牌 | FuHeng |
| 英文名 | A2780 (STR) |
| 货号 | FH0140 |
| 规格 | 1×10⁶cells/T25培养瓶 |
| 价格 | 2000.0 |
| 培养 | DMEM(高糖)+10%FBS |
| 别称 | A-2780; 2780; A2780S |
| 形态特征 | 上皮细胞样 |
| 生长特性 | 贴壁生长 |
| 培养条件 | 气相：空气，95%；CO2,5%温度：37℃ |
| 传代方法 | 1：2传代 |
| 组织来源 | 卵巢浆液性囊腺癌 |
| 细胞简介 | A2780 细胞系由 J. Fogh 和 J. Trempe 于 1977 年建立。该细胞在体外培养时呈上皮样形态，贴壁生长。它具有一些典型的卵巢癌细胞特征，如高增殖能力、特定的细胞表面抗原表达等。A2780 细胞常被用于卵巢癌的基础研究，包括肿瘤细胞的生物学行为、信号转导通路、药物敏感性等方面的研究。此外，它还可用于筛选和评估新型抗卵巢癌药物的疗效，为卵巢癌的临床治疗提供实验依据。 |
| 培养基 | A2780完全培养基 |
富衡相关文献
| 论文标题 | DOI | 发表时间 | 期刊 | 影响因子 | 作者列表 |
| Drug combination discovery assisted by AI and untargeted ｍmbedbolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment | 10.3389/fphar.2025.1702014 | 2025-11-26 | Frontiers in Pharmacology | 4.8 | Dong Wang, Baiwang Chu, Tingjie Wen, Xueyu Wang, Ying Li, Hanning Chen, Zhao Zhang, Hua Sun |
| Biomimetic Chitosan Nanogels Codeliver Drug/Small Activating RNA for Metastasis-Inhibited Necroptosis Therapy of Ovarian Cancer | 10.1021/acs.biomac.5c00539 | 2025-06-20 | BIOMACROMOLECULES | 5.4 | Danni Li, Aiyu Li, Lu Zhang, Yunfei Huang, Rui Guo, Xiangyang Shi, Xueyan Cao |
| Oncolytic vaccinia virus harboring aphrocallistes vastus lectin exerts anti-tumor effects by directly oncolysis and inducing immune response through enhancing ROS in human ovarian cancer | 10.1016/j.bbrc.2024.150355 | 2024-07-04 | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2.5 | Guohui Zhang, Qiang Wang, Rentao Yuan, Yanan Zhang, Ke Chen, Jianlei Yu, Ting Ye, Xiaoyuan Jia, Yanrong Zhou, Gongchu Li, Kan Chen |
| Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer | 10.1007/s10495-024-01956-3 | 2024-04-13 | APOPTOSIS | 6.1 | Li Xin, Guan Wencai, Liu Huiqiang, Yuan Jia, Wang Fanchen, Guan Bin, Chen Junyu, Lu Qi, Xu Guoxiong, Zhang Lingyun |
| Mechanism of Sophorae Flavescentis Radix against ovarian cancer via new pharmacology, molecular docking, and experimental verification | 10.1007/s00210-024-03065-z | 2024-04-02 | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 3.1 | Fu XuLi, Liang Feimei |
| Synthesis of Taxifolin-Loaded Polydopamine for Chemo-Photothermal-Synergistic Therapy of Ovarian Cancer | 10.3390/molecules29051042 | 2024-02-28 | MOLECULES | 4.2 | Yang Lu, Xinglong Liu, Ting Zhao, Chuanbo Ding, Qiteng Ding, Ning Wang, Shuang Ma, Lina Ma, Wencong Liu |
| Inhibit ALDH3A2 reduce ovarian cancer cells survival via elevating ferroptosis sensitivity | 10.1016/j.gene.2023.147515 | 2023-05-27 | GENE | 3.5 | Hao Dong, Linsheng He, Qiran Sun, Jiao Zhan, Jiaqi Li, Xiaoming Xiong, Lingling Zhuang, Shuqing Wu, Yuan Li, Chen Yin, Quan He |
| UQCRFS1 serves as a prognostic biomarker and promotes the progression of ovarian cancer | 10.1038/s41598-023-35572-z | 2023-05-23 | Scientific Reports | 4.6 | Sun Qiran, Li Jiaqi, Dong Hao, Zhan Jiao, Xiong Xiaoming, Ding Jiashan, Li Yuan, He Linsheng, Wang Jing |
| CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1α-glycolysis signaling pathway | 10.1038/s41419-022-05129-5 | 2022-08-04 | Cell Death & Disease | 9.685 | Jin Yunfeng, Bian Saiyan, Wang Hui, Mo Jiahang, Fei He, Li Li, Chen Tong, Jiang Hua |
| Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer | 10.7150/jca.69574 | 2022-03-14 | Journal of Cancer | 4.478 | Mandika Chetry, Adheesh Bhandari, Yue Lin |
| Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer | 10.1155/2022/3554100 | 2022-02-09 | DISEASE MARKERS | 3.464 | Lekai Nie, Chen Zhang, Haiyun Song, Qianqian Zhao, Lei Cheng, Peihai Zhang, Xingsheng Yang |
| Sulfated Polysaccharide From Undaria Pinnatifida Induces Apoptosis and Inhibits Proliferation, Migration, and Invasion in Ovarian Cancer via Suppressing the Hedgehog Signaling Pathway | 10.3389/fmats.2021.795061 | 2021-12-13 | Frontiers in Materials | 3.515 | Yang Yi, Zhang Qin, Xu Yongping, Chen Gang, Qiu Yukuan |
| Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer | 10.1016/j.bmc.2021.116512 | 2021-11-10 | BIOORGANIC & MEDICINAL CHEMISTRY | 3.641 | Hong Ding, Yuan Pei, Yuanqing Li, Wen Xu, Lianghe Mei, Zeng Hou, Yiman Guang, Liyuan Cao, Peizhuo Li, Haijing Cao, Jinlei Bian, Kaixian Chen, Cheng Luo, Bing Zhou, Ting Zhang, Zhiyu Li, Yaxi Yang |
| UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway | 10.1186/s13048-021-00877-y | 2021-09-17 | Journal of Ovarian Research | 4.234 | Hu Wenjing, Li Min, Chen Youguo, Gu Xinxian |
| Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages | 10.18632/oncotarget.9246 | 2016-05-09 | Oncotarget | 5.008 | Xiang Ying, Quanfeng Wu, Xiaoli Wu, Qinyi Zhu, Xinjing Wang, Lu Jiang, Xin Chen, Xipeng Wang |
上海衡生物科技有限公司
上海富衡生物科技有限公司（以下简称“富衡”）是主要从事生物科技，医药科技领域内的技术开发，技术咨询，技术服务的高新技术企业。是一家专注于细胞相关技术，服务及产品的高科技生命科学和生物技术领域企业。
富衡提供专业的细胞鉴定服务（采用ATCC细胞鉴定准－－STR基因分型技术），并建立完善鉴定，种类齐全的细胞资源库，能为广大科研工作者在发表高质量文章时提供可靠的“细胞鉴定依据”。公司拥有一个蓬勃朝气的年轻团队，不断进取，我们密切注视细胞技术领域的发展，并且于员工的技术和素质培训。团队中博士硕士以上学历人士达80％，有很强的技术支持及研发能力。
专注于细胞培养 PARTNERS 合作伙伴
热门标签：人卵巢癌细胞A2780,A2780,A2780细胞
